Accelovance, Inc., based in Rockville, MD, is a clinical services company specializing in high patient throughput from recruitment through study completion. Accelovance has developed a model to increase the reliability and productivity on Phase I (outpatient) and Phase II-IV trials. Accelovance enhances this offering with flexible CRO services to meet a Sponsor’s specific trial needs.

Each study is approached with the intent to complete enrollment BEFORE the study starts. With critical planning and full control of patient recruitment and clinical facility operations, Accelovance is committed to delivering high quality, predictable, and cost effective clinical trials.

Accelovance (China) Corp., Ltd., a wholly foreign owned enterprise of Accelovance, Inc., is a clinical CRO and market commercialization services company with offices in Beijing and Shanghai, P.R. China. Accelovance (China) fully leverages its relationship with its parent company, U.S. to deliver high quality clinical services in compliance with international standards. In addition, Accelovance (China) works with sponsors to realize the value of the China pharmaceutical market, which is the fastest growing in the world.